Home/Pipeline/THEO-260

THEO-260

Ovarian Cancer

Phase 1/2Active

Key Facts

Indication

Ovarian Cancer

Phase

Phase 1/2

Status

Active

Company

Theolytics

About Theolytics

Theolytics is a clinical-stage biotech founded in 2017 in Oxford, UK, focused on developing next-generation oncolytic virus therapies for solid tumors. Its core innovation is the ADENOVO platform, which uses Darwinian selection on actual patient tumors to identify viruses optimized for efficacy, delivery, and manufacturing. With a lead candidate in Phase 1/2 trials for ovarian cancer and a pipeline targeting other indications, the company aims to overcome the significant barriers posed by the tumor stroma and microenvironment.

View full company profile

Therapeutic Areas

Oncology

Other Ovarian Cancer Drugs

Drug	Company	Phase	Status
EXO‑Ovarian Cancer Test	INOVIQ	Phase 2/3	Active
CAR‑iNK‑OvCa	Cartherics	Preclinical	Active
MagSense™ FR Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Yondelis (trabectedin)	PharmaMar	Approved	Commercial/Lifecycle
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
NP-G2-044 + Chemotherapy Agents	Novita Pharmaceuticals	Phase 2a	Active (combination strategy)
Ivospemin (SBP-101)	Panbela Therapeutics	Phase 2	Active
Ovarian Cancer Early Detection Assay	GenEndeavor	Pre-clinical	Active
INVAC-1	Invectys	Phase 2	Active
Folate Receptor-Targeted PCC	Indi Molecular	Preclinical	Active
Immunomodulator Platform	OmniCyte	Pre-clinical	Active
Platform Candidate	FLAG Therapeutics	Preclinical	Active